Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PACB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A life science technology company designing and manufacturing advanced HiFi long-read sequencing solutions (Revio and Vega platforms) for genomic research and clinical applications.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenue | $39,007 | $39,766 | $76,185 | $76,919 |
| Gross Profit | $12,638 | $14,684 | $25,479 | $13,313 |
| Gross Margin | 32.4% | 36.9% | 33.4% | 17.3% |
| Operating Loss | $(44,610) | $(44,853) | $(52,967) | $(473,787) |
| Net Loss | $(44,741) | $(41,930) | $(53,016) | $(468,005) |
| Cash & Investments | $236,873 (as of June 30, 2026) | |||
| Convertible Debt (Principal) | $641.0 million ($200M 2029 Notes + $441M 2030 Notes) |
Material Changes vs. Prior Period
- Revenue Stability: Total revenue remained relatively flat year-over-year for both the quarter (-2%) and six months (-1%). Product revenue was flat, while service revenue declined slightly.
- Significant Improvement in Operating Loss: Operating loss for the six months ended June 30, 2026, decreased by $420.8 million compared to the prior year. This improvement is primarily due to the absence of $382.4 million in one-time restructuring and impairment charges recorded in the first half of 2025 (including $359.3 million in accelerated amortization and $15.0 million in IPR&D impairment).
- Asset Disposal Gain: The company recorded a $45.8 million gain on the disposal of short-read sequencing assets to Illumina Cambridge Limited in Q1 2026, which offset operating expenses.
- Legal Settlement: The company incurred $15.4 million in settlement charges related to a patent litigation settlement with Personal Genomics of Taiwan, Inc. (PGI) in the first half of 2026.
- Product Mix: Consumable revenue increased 7% year-over-year for the six-month period, driven by Revio installed base growth and the launch of SPRQ-Nx chemistry. Instrument revenue decreased 10% due to lower Vega unit sales and strategic pricing on Revio.
Guidance, Outlook, and Risks
- Strategic Outlook: Management expects revenue to be greater in the second half of 2026, driven by clinical adoption, SPRQ-Nx consumable growth, and the Basecamp Research program.
- Expense Reduction: On July 30, 2026, the Board approved a new restructuring plan involving a reduction in force of approximately 40 employees (8% of workforce). The company expects to incur $2.0 million in pre-tax charges in Q3 2026 and aims to reduce annualized operating expenses by $30–$40 million by the end of 2027.
- Liquidity: The company holds $236.9 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for more than 12 months, though the company continues to incur operating losses.
- Leadership Change: Mark Van Oene was appointed President and CEO effective August 5, 2026, succeeding Christian Henry.
- Key Risks:
- Supply Chain & Costs: Rising costs for computing components (specifically memory) and potential supply constraints.
- Regulatory & Trade: Uncertainty regarding U.S. government funding (NIH), export controls, and tariffs impacting international sales and component sourcing.
- Debt Obligations: Significant convertible senior notes maturing in 2029 and 2030; potential dilution upon conversion.
Investor Verification Checklist
- Run-Rate Sustainability: Verify if the Q2 2026 operating loss of ~$44.6 million represents a sustainable run-rate absent the massive one-time charges of 2025.
- Instrument Sales Trajectory: Confirm the impact of the Vega sales decline (26 units in Q2 2026 vs. 38 in Q2 2025) on future revenue growth.
- Debt Covenants: Review the negative covenants associated with the 2029 Notes held by SoftBank Northstar LP, which restrict additional indebtedness.
- Restructuring Execution: Monitor the execution of the new Q3 2026 workforce reduction and the realization of the targeted $30–$40 million annualized expense savings.
- PGI Settlement Impact: Assess the long-term financial impact of the PGI settlement, including future payments contingent on 2026 revenue targets.